Dasatinib is an oral potent ATP-competitive inhibitor of Bcr-Abl, cKIT and Src family kinases which exhibits good efficacy in patients with Imatinib-resistant chronic myelogenous leukemia. Dasatinib treatment is associated with mild thrombocytopenia and an increased risk of bleeding but its biological effect on megakaryocytopoiesis and platelet production is unknown. In this study, we show that Dasatinib causes mild thrombocytopenia in mice without altering platelet half-life suggesting that Dasatinib inhibits platelet formation. On the other hand, the number of megakaryocytes in bone marrow of Dasatinib-treated mice is increased and the ploidy of megakaryocytes derived from bone marrow progenitor cells in vitro is elevated in the presence of Dasatinib. Furthermore, a significant delay in platelet recovery following immune-induced thrombocytopenia is observed in Dasatinib-treated mice even though the number of megakaryocytes in bone marrow is increased relative to controls at all time points. Interestingly, migration of megakaryocytes towards a gradient of SDF1α and the formation of proplatelets in vitro are abolished by Dasatinib. We propose that Dasatinib causes thrombocytopenia as a consequence of ineffective thrombopoiesis promoting megakaryocyte differentiation on one hand but impairing megakaryocyte migration and proplatelet formation on the other hand.
Introduction
Dasatinib is a novel potent ATP-competitive inhibitor of multiple tyrosine kinases including Bcr-Abl, Src family kinases (SFKs) (e.g. Fyn, Yes, Src and Lyn), c-KIT, ephrin A receptor and platelet-derived growth factor-β (PDGF-β) receptor kinases 1 . It is widely used for the treatment of Imatinib-resistant chronic myelogenous leukemia (CML) [2] [3] [4] . CML is a malignant proliferative disorder of hematopoietic stem cells 5 , which is characterized by the presence of a constitutive activated form of the Abl tyrosine kinase due to a fusion product between Bcr and Abl resulting from the translocation between chromosome 9 and 22 that is the hallmark of this disease Six members of the Src family of tyrosine kinases have been shown to be expressed in MKs and platelets 15, 16 . SFKs play critical roles in platelet activation by a variety of glycoprotein receptors, including GPVI, CLEC-2, αIIbβ3 and GPIb-IX-V. This includes a key role in mediating changes in cytoskeletal organization leading to cell spreading and motility 17 . Recently, we have demonstrated that SFKs also play a critical role in integrininduced MK spreading, migration and activation of PLCγ2 in primary BM-derived MKs 18 .
MKs treated with inhibitor of SFKs are unable to spread or migrate towards a gradient of In this study, we have investigated the effect of Dasatinib on megakaryocytopoiesis and platelet production in a murine model. We show that Dasatinib causes thrombocytopenia in mice to a similar level of that observed in human patients and we confirm that this is due to a defect in platelet production rather than a shortened platelet half-life. Further, we also show that MK differentiation in vitro is increased in the presence of Dasatinib but that MK migration and proplatelet formation are abolished. We therefore conclude that the thrombocytopenia observed in Dasatinib-treated patients is the result of an impairment of MK migration and proplatelet formation rather than a defect in MK growth or an increase in platelet consumption. 
Materials and Methods

Chemicals
Recombinant murine stem cell factor (SCF), TPO and SDF1α were purchased from PeproTech (London, UK). Sheep anti-rat IgG Dynabeads, biotin-conjugated rat anti-mouse CD45R/B220, purified rat anti-mouse CD16/CD32, FITC-conjugated anti-mouse GPIIb, streptavidin-PE and rat anti-mouse GPIIb antibodies were from BD Pharmingen (Oxford, UK). Anti-mouse Ly-6G and biotin anti-mouse CD11b antibodies were from eBioscience (Wembley, UK). FITC-conjugated anti-mouse CXCR4 and goat anti-rat IgG FITC antibodies were obtained from R&D Systems (Abingdon, UK). Goat anti-rat IgG Alexa Fluor 488, rhodamine-phalloidin, Stempro medium and Dulbecco's modified Eagle's medium were from GIBCO, Invitrogen (Paisley, UK). Anti-mouse GPIbα antibody was from Emfret Analytics (Wurzburg, Germany). Anti-PLCγ2 (DN84) and anti-Syk (BR15) polyclonal antibodies were gifts from Dr. Joseph Bolen (DNAX Research Institute, Palo Alto, CA). Dasatinib (Sprycel) was purchased from LC Laboratories (Woburn, USA). Bovine serum albumin (BSA; fatty acid-free), Ribonuclease A and biotin-N-hydroxysuccinamide (Biotin-NHS) were purchased from Sigma-Aldrich (Gillingham, UK). Bovine plasma fibronectin was purchased from Calbiochem (Nottingham, UK). The anti-Src pan, anti-SFK activation loop phospho-Tyr-418 and anti-Src phospho-Tyr-529 antibodies were obtained from Invitrogen (Paisley, UK). The anti-phospho-MLC (Thr18/Ser19) and anti-MLC antibodies were purchased from Cell signalling technology (Hertfordshire, UK).
Mice
Wild type littermates were used as controls. All procedures were undertaken with United Kingdom Home Office approval in accordance with the Animals (Scientific Procedures) Act of 1986 (Project License No: 40/2721, 40/9038). CD41-YFPki/+ mice were generated as For personal use only. on April 19, 2017. by guest www.bloodjournal.org From previously described 10, 22 . For in vivo imaging, the experimental procedures performed on animals were undertaken with the requirements of the German legislation.
Platelet aggregation
Blood was collected from C0 2 -asphyxiated mice by cardiac puncture into heparin (10U/ml) and PRP was prepared by centrifugation at 200 g for 6 minutes. Platelet aggregation was measured using lumi-aggregometer (Chrono-Log, Havertown, PA, USA).
Preparation and culture of mouse megakaryocytes
Mature MKs from mouse BM were defined as the population of cells generated using the methodology previously described 18, 23, 24 . In brief, BM cells were obtained from femora and tibiae of mice by flushing, and cells expressing one or more of the lineage specific markers on their surface (CD16/CD32+, Gr1+, B220+, CD11b+) were depleted using immunomagnetic beads (sheep anti-rat IgG Dynabeads). The remaining population was cultured in 2.6% serum-supplemented Stempro medium with 2 mM L-glutamine, penicillin/streptomycin and 20 ng/mL murine SCF at 37°C under 5% CO 2 for 2 days. Cells were then cultured for a further 4 days in the presence of 20 ng/mL of SCF and 50 ng/mL of TPO. After 4 days of culture in the presence of TPO, the cell population was enriched in mature MKs using a 1.5% / 3% BSA gradient under gravity (1×g) for 45 minutes at room temperature as described 18 .
Megakaryocyte ploidy and flow cytometry
Expression levels of GPIIb and CXCR4 were measured by flow cytometry using specific antibodies. Polyploidy of mature MKs isolated by BSA gradient was analyzed after antiGPIIb labelling and DNA staining with 0.01 mg/mL propidium iodide. GPIIb positive cells 
Cell migration assay
Chemotaxis was assessed using the Dunn chemotaxis chamber (Weber Scientific International, Teddington, UK) as described previously 25 . To investigate the effect of Dasatinib in migration, the Dunn chamber outer well was filled with the medium containing SDF1α (300 ng/mL) and the Src family kinases inhibitor Dasatinib (10 μM). Time-lapse images were digitally captured every minute for 3 hours using a Zeiss 20× 
Immune thrombocytopenia
Thrombocytopenia was induced in 8-12 weeks old WT and Dasatinib-treated mice (5 mg/kg/day) by intraperitoneal injection of anti-mouse GPIbα antibody (2 μg/g of mouse), as previously described 18, [26] [27] [28] . Blood samples were collected pre-injection (time = 0) and then at 3, 48, 72, 96, 120, 144 and 172 hours post-injection by tail bleeding. Platelet counts were measured using an ABX Pentra 60 Haematology Analyzer (Block Scientific, Inc).
Platelet half life
Measurement of platelet lifespan was performed as previously described 29, 30 . Mice were injected intravenously with 150 μl of 4 mg/mL biotin-NHS. At various time points after
For personal use only. on April 19, 2017. by guest www.bloodjournal.org From injection, whole blood was collected into buffer containing 10% FBS and 5 mM ethylenediaminetetraacetic acid (EDTA). 10 μl of blood was washed, pelleted at 1200 g for 10 minutes, and stained with anti-mouse GPIIb-FITC and streptavidin-PE for 1 hour on ice.
Samples were washed again and the percentage of biotin-labelled platelets (GPIIb+ biotin+) was determined by flow cytometry. Platelet survival was estimated from the decay curve of the percentage of biotinylated platelets over time.
Megakaryocyte spreading and proplatelet formation
Coverslips were coated with fibronectin (20 µg/mL), fibrinogen (100 μg/mL) or BSA (100 μg/mL) overnight at 4°C, blocked with denatured BSA (5 mg/mL) for 1 hour at room temperature and washed with PBS before use. For spreading experiments, mature MKs were incubated 15 minutes with Dasatinib (10 μM) and plated on fibronectin-coated surface for 3 hours at 37°C. For proplatelet formation, mature MKs were incubated 15 minutes with Dasatinib (10 μM) and plated on fibrinogen-coated surface for 5 hours at 37°C. Adherent MKs and MKs forming proplatelets were fixed with formalin 4%, permeabilized with triton 0.1%. Actin fibres were stained with rhodamine-phalloidin and MKs forming proplatelets with anti-mouse GPIIb-FITC antibody.
Megakaryocyte biochemistry
To study tyrosine phosphorylation events in response to adhesion to fibronectin matrix, 6
well-plates Petri dishes were coated with fibronectin (20 µg/mL) or BSA (100 μg/mL) overnight at 4°C then blocked with denatured BSA (5 mg/mL) for 1 hour. After BSA gradient, mature MKs were harvested 2 hours at 37°C and then were added to fibronectin or BSA coated dishes for 3 hours. MKs were either pre-treated with DMSO (<0.1%) or with Dasatinib (10 μM) for 15 minutes at 37°C prior to plating. MKs adherent to fibronectin or in 
Two-photon intravital imaging of bone marrow
Preparation of mouse calvarial BM for intravital imaging was performed according to the protocol described previously 10, 31 . Mice were anesthetized with 5% Vol. Isofluran InspectorPro software (LaVisionBioTec). For three-dimensional acquisition, stacks were acquired at a wavelength 920 nm with a vertical spacing of 3 µm to cover an axial depth of 30-100 µm (for YFP). Subsequently the same stacks were acquired at a wavelength of 800 nm (for TRITC). 3D volume structures were reconstructed using Volocity (Improvision, Lexington, MA, USA) at wavelength 920 nm and 800 nm. Reconstructed 3D structures were used to measure the distance between MKs and vasculature. All mice were treated with murine TPO (ImmunoTools, Friesoythe, Germany) 8 μg/kg/day for 3 days before imaging.
A previous study has already shown normal physiology of thrombopoiesis after TPO treatment 10 .
Immunohistochemistry
Femora and spleens were obtained from control and Dasatinib-treated mice. Samples were fixed in buffered formalin and embedded in paraffin. Sections (5 μm) were stained with hematoxilin and eosin (H&E) and examined by light microscopy with a 40X objective.
Cryosections (5 μm) of murine femora were fixed in 4% PFA, blocked in 3% BSA-tween 0.05%, stained with anti-mouse GPIIb (1 mg/mL) and then GPIIb was detected with secondary goat anti-rat IgG Alexa Fluor 488 antibody. Three mice were used for each condition, eight to ten field of view per tissue sample, through 5 marrow sections.
Fluorescence images were obtained using a Zeiss Axiovert 200 inverted high-end microscope (Welwyn Garden City, UK) microscope with a 20X objective.
Statistical analysis
Experiments were performed a minimum of 3 times and images shown are representative data from 1 experiment. 
Results
Dasatinib induces thrombocytopenia in mice
The effect of in vivo administration of Dasatinib on the platelet count was investigated. The dose of Dasatinib (5 mg/kg/day) causes an increase in tail bleeding times at 4 and 24 h, and with full recovery by 48 h 20 . Consistent with this, we have shown that this dose completely blocks ex vivo collagen-induced platelet aggregation for up to 6 hours (Supplementary Figure   1) . Treatment with Dasatinib caused a reduction in the platelet number over the first two days which reached a plateau at approximately 70% of the original count ( Figure 1A ). This is similar to the decrease in count in patients with CML treated with Dasatinib 19, 32 .
Thrombocytopenia was reversed within 4 days upon discontinuation of treatment ( Figure   1B ).
Dasatinib-induced thrombocytopenia is not due to an effect on platelet consumption
To determine whether an increase in platelet consumption could be responsible for the thrombocytopenia, the half-life of circulating platelets was measured following biotinylation as previously described 29, 30 . Dasatinib had no significant effect on platelet consumption relative to control mice ( Figure 2A ). In contrast, the number of new, non-biotinylated platelets was impaired by approximately 30% in line with the reduction in platelet count described above ( Figure 2B ). These results demonstrate that the thrombocytopenia induced by Dasatinib is mediated by defective platelet production but not by altered platelet consumption.
Dasatinib impairs platelet recovery after immune-induced thrombocytopenia
Further experiments were undertaken to investigate whether Dasatinib also plays a role in platelet formation following an acute decrease in platelet count. To investigate this, the
count was reduced to less than 5% of control levels by injection of antiGPIbα antibody. A significant delay in platelet recovery was observed in Dasatinib-treated mice following normalization of the data for the different steady-state level of platelets relative to the control group (Figure 3) . Therefore, Dasatinib not only impairs platelet production at steady state but also in conditions that require an acute increase in thrombopoiesis.
Dasatinib treatment increases the number of megakaryocytes in bone marrow
The effect of Dasatinib treatment on the number of MKs in murine BM was investigated.
Analysis of MK sections using H&E staining ( 
The effect of Dasatinib on megakaryocytopoiesis, megakaryocyte migration and proplatelet formation in vitro
The molecular basis of the effects of Dasatinib were further investigated using primary cultures of MKs grown from BM-derived progenitors cells as previously described 18 .
Dasatinib (10 μM) was used at a concentration that is known to be sufficient to inhibit collagen-induced platelet activation through a Src kinase-dependent pathway. In the presence 18 . In keeping with this mechanism, we observed a loss of phosphorylation of these proteins in the presence of Dasatinib (Figure 6Di-iii) .
We also considered the possibility that Dasatinib could also affect the function or expression of the SDF1α chemokine receptor, CXCR4, on MKs. Treatment with the Src kinase inhibitor had no effect on expression of CXCR4 ( Supplementary Figure 2A) . On the other hand, Dasatinib inhibits SDF1α-induced aggregation of mouse platelets (Supplementary Figure 2B) . This is likely to reflect the role of Src kinases in supporting platelet aggregation by Gi-coupled receptors as recently reported for activation of human platelets by adrenaline 35 . Importantly, this study demonstrated that Dasatinib did not block inhibition of adenylyl cyclase by adrenaline thereby indicating that Src kinases synergise with other Gi-regulated pathways to mediate platelet activation. In a similar way, Src kinases may contribute to migration of MKs to SDF1α and loss of this could contribute to the reduced aggregation.
We therefore concluded that inhibition of MK migration and/or proplatelet formation is the likely mechanisms through which Dasatinib causes thrombocytopenia.
Localisation of megakaryocytes in bone marrow
To investigate the molecular basis of the thrombocytopenia in further details, we asked whether MKs from Dasatinib-treated mice are localised to the osteoblastic niche. This was investigated using 2-photon intravital microscopy in BM in the mouse skull. MKs were identified using CD41-YFP ki/+ mice in which enhanced yellow fluorescent protein (YFP) was expressed as a targeted transgene from the endogenous gene locus for the αIIb-integrin We demonstrate that in vivo Dasatinib rapidly and reversibly induces thrombocytopenia and increases the number of mature MKs in the BM. We further show that in vitro MK migration in response to SDF1α, MK spreading and proplatelet formation are abolished by Dasatinib.
These effects, combined with its inhibitory effects on platelet activation 20, 21 , may explain the bleeding in patients treated for Imatinib-resistant CML.
For 
Conflict of Interest
The authors declare no competing financial interests.
For Dasatinibtreated mice
